Objective To systematically evaluate the clinical efficacy and safety of kidney-tonifying and blood-activating(KT-BA)therapy for treating patients with decreased ovarian reserve(DOR).Methods China National Knowledge Infrastructure(CNKI),Wanfang Data,VIP,Chinese Biomedical Database(CBM),PubMed,Embase,and Co-chrane Library were searched from their inception until December 31,2022,for randomized controlled trials(RCTs)of KT-BA therapy in the treatment of DOR.Meta-analysis was conducted using RevMan 5.3 to assess the impact of this ther-apy on follicle-stimulating hormone(FSH),follicle-stimulating hormone/luteinizing hormone(FSH/LH)ratio,estradiol(E2),traditional Chinese medicine(TCM)syndrome scores,clinical comprehensive efficacy,and adverse reactions.Results Eleven articles involving 781 patients were included.The Meta-analysis results showed that compared with the control group,the observation group effectively reduced TCM syndrome scores[RR(95％CI)=-2.82(-3.57,-2.07),Z=7.35,P＜0.000 01],increased E2 levels[SMD(95％CI)=0.33(0.14,0.52),Z=3.41,P=0.000 6],and improved clinical comprehensive efficacy[RR(95％CI)=1.18(1.06,1.33),Z=2.89,P=0.004].There was no significant ad-vantage in improving FSH/LH ratio[MD(95％CI)=-0.04(-0.17,0.08),Z=0.67,P=0.50],and the effect on FSH values varied among subgroups,making it difficult to determine an advantage.Adverse reaction reports were limited.Conclusion KT-BA therapy can effectively improve E2 levels,reduce TCM syndrome scores and enhance clinical symp-toms in patients with DOR.It is a promising treatment method with potential application,though its safety needs further e-valuation.However,the quantity and quality of included literature are limited,and higher-quality research is required for further confirmation.
Kidney-Tonifying and Blood-Activating TherapyMeta-AnalysisDecreased Ovarian ReserveHormone Replacement TherapyClinical Efficacy
维普
万方数据
